Roche Thailand
Roche Thailand is the Thai subsidiary of Roche Holding AG (Swiss-parent global pharmaceutical, diagnostics group). ~5% Thai market share by value. Therapeutic focus: oncology (Avastin, Herceptin, Rituxan, Perjeta, Kadcyla, Tecentriq, Phesgo, Vabysmo for ophthalmology), neuroscience (Ocrevus for MS), haematology, rare disease. Roche Pharma operations in Thailand complemented by Roche Diagnostics Thailand (in-vitro diagnostics, clinical chemistry, molecular diagnostics) β not covered directly in this profile but relevant context. Biologic-heavy portfolio faces progressive biosimilar competition including GPO-produced, imported trastuzumab, rituximab, bevacizumab biosimilars.
Snapshot
Headline numbers a buyer checks first.
Thai market share
~5% by value
FY2024
Biologic-heavy; higher per-unit ASP than generic peers
Parent global revenue
CHF 51.7B
FY2024
Roche Holding AG FY2024; pharma division CHF 38.6B
Key Thailand products
Herceptin, Avastin, Rituxan, Vabysmo, Hemlibra, Ocrevus
FY2024
Parent
Roche Holding AG (SIX:ROG)
Subsidiary since 1970
Thailand subsidiary founded
1970
Historical
Over 54 years of continuous Thai presence
Diagnostics arm
Roche Diagnostics Thailand (separate entity)
FY2024
IVD, molecular diagnostics, not covered in this profile
What this subsidiary actually does
Roche Thailand imports, markets, and distributes Roche Holding AG-originated biologic, specialty pharmaceutical products. Oncology biologics are the franchise core: Avastin (bevacizumab), Herceptin (trastuzumab), Rituxan/MabThera (rituximab), Perjeta (pertuzumab), Kadcyla (T-DM1), Tecentriq (atezolizumab PD-L1), Phesgo (subcutaneous pertuzumab, trastuzumab). Ophthalmology: Vabysmo (faricimab, AMD). Neuroscience: Ocrevus (ocrelizumab, multiple sclerosis). Haematology, rare disease: Hemlibra (emicizumab, haemophilia A). Channels: MoPH, UCS high-cost-drug programme, hospital direct, specialty pharmacy.[]
Strategic position: Roche Thailand is Thailand's deepest biologic, specialty oncology subsidiary. Structural challenge: biosimilar competition compresses Herceptin, Rituxan, Avastin revenue as they enter NLEM biosimilar-inclusion rounds. Offset via new-product launches (Vabysmo, Hemlibra, Phesgo, Tecentriq new indications), Kadcyla, Perjeta, personalised medicine. Roche's global pipeline in neuroscience, oncology, rare disease provides multi-year subsidiary trajectory.[, ]
Portfolio dynamics: biosimilar compression vs new-product pipeline
The core investment thesis on Roche Thailand is a two-sided ledger.
Headwind
Herceptin, Rituxan, Avastin β biosimilar erosion
Roche's original oncology biologic trio (Herceptin trastuzumab, Rituxan rituximab, Avastin bevacizumab) have all lost patent protection and face Thai-FDA-approved biosimilar competition. GPO produces domestic trastuzumab and bevacizumab biosimilars; imported biosimilars are entering via MOPH procurement. Revenue from these three products in Thailand has been declining 15-25% per year as biosimilar tender success expands.[]
Tailwind
Vabysmo: ophthalmology challenger winning AMD market
Vabysmo (faricimab) for age-related macular degeneration and diabetic macular oedema targets the same indication as Novartis Lucentis. Vabysmo's dual-mechanism and extended dosing interval (every 4 months vs monthly for Lucentis) is gaining Thai ophthalmologist preference. This is Roche's strongest near-term growth product in Thailand's specialty pharma segment.[]
Tailwind
Hemlibra: haemophilia A franchise
Hemlibra (emicizumab) for haemophilia A with and without inhibitors is Roche's most differentiated rare-disease product globally. Thailand's haemophilia patient population is served by a government rare-disease access programme. Hemlibra's subcutaneous dosing (vs IV factor infusions) has driven adoption β Roche's global Hemlibra sales reached CHF 4.4B in FY2024, with Thailand a small but growing access market.[]
Tailwind
Ocrevus in multiple sclerosis β underserved Thai indication
Ocrevus (ocrelizumab) for relapsing-remitting and primary-progressive multiple sclerosis is Roche's neuroscience anchor. MS is underdiagnosed in Thailand; neurology centre expansion is broadening the patient-identification funnel. Ocrevus is approved in Thailand through private hospital neurology programmes β a small but premium-priced market with limited price-competition from generics.[]
Personalised medicine: the diagnostics integration advantage
Roche Holding AG uniquely owns both a leading pharmaceutical division and the world's largest in-vitro diagnostics business. In Thailand, Roche Diagnostics Thailand (a separate legal entity) provides companion diagnostic assays that unlock Roche pharma products: HER2 IHC/FISH testing for Herceptin eligibility, PD-L1 testing for Tecentriq, FISH cytogenetics for haematology treatments. This diagnostics-pharma lock-in is a competitive moat unavailable to competing oncology MNCs who rely on third-party diagnostic labs.[]
The companion-diagnostic integration means oncology centres using Roche Diagnostics platforms generate patient-selection data that feeds Roche pharma prescribing. Thai large cancer centres (Mahidol Siriraj, Chulalongkorn, Ramathibodi, Bangkok Hospital Cancer Centre) are the critical accounts where this flywheel compounds over time.
Portfolio dynamics: biosimilar compression vs new-product pipeline
The core investment thesis on Roche Thailand is a two-sided ledger.
Headwind
Herceptin, Rituxan, Avastin β biosimilar erosion
Roche's original oncology biologic trio (Herceptin trastuzumab, Rituxan rituximab, Avastin bevacizumab) have all lost patent protection and face Thai-FDA-approved biosimilar competition. GPO produces domestic trastuzumab and bevacizumab biosimilars; imported biosimilars are entering via MOPH procurement. Revenue from these three products in Thailand has been declining 15-25% per year as biosimilar tender success expands.[]
Tailwind
Vabysmo: ophthalmology challenger winning AMD market
Vabysmo (faricimab) for age-related macular degeneration and diabetic macular oedema targets the same indication as Novartis Lucentis. Vabysmo's dual-mechanism and extended dosing interval (every 4 months vs monthly for Lucentis) is gaining Thai ophthalmologist preference. This is Roche's strongest near-term growth product in Thailand's specialty pharma segment.[]
Tailwind
Hemlibra: haemophilia A franchise
Hemlibra (emicizumab) for haemophilia A with and without inhibitors is Roche's most differentiated rare-disease product globally. Thailand's haemophilia patient population is served by a government rare-disease access programme. Hemlibra's subcutaneous dosing (vs IV factor infusions) has driven adoption β Roche's global Hemlibra sales reached CHF 4.4B in FY2024, with Thailand a small but growing access market.[]
Tailwind
Ocrevus in multiple sclerosis β underserved Thai indication
Ocrevus (ocrelizumab) for relapsing-remitting and primary-progressive multiple sclerosis is Roche's neuroscience anchor. MS is underdiagnosed in Thailand; neurology centre expansion is broadening the patient-identification funnel. Ocrevus is approved in Thailand through private hospital neurology programmes β a small but premium-priced market with limited price-competition from generics.[]
Personalised medicine: the diagnostics integration advantage
Roche Holding AG uniquely owns both a leading pharmaceutical division and the world's largest in-vitro diagnostics business. In Thailand, Roche Diagnostics Thailand (a separate legal entity) provides companion diagnostic assays that unlock Roche pharma products: HER2 IHC/FISH testing for Herceptin eligibility, PD-L1 testing for Tecentriq, FISH cytogenetics for haematology treatments. This diagnostics-pharma lock-in is a competitive moat unavailable to competing oncology MNCs who rely on third-party diagnostic labs.[]
The companion-diagnostic integration means oncology centres using Roche Diagnostics platforms generate patient-selection data that feeds Roche pharma prescribing. Thai large cancer centres (Mahidol Siriraj, Chulalongkorn, Ramathibodi, Bangkok Hospital Cancer Centre) are the critical accounts where this flywheel compounds over time.
Watchpoints
Biosimilar compression on legacy biologics
Herceptin, Rituxan, Avastin NLEM biosimilar inclusion timeline.
New-product launch cadence
Vabysmo, Hemlibra, Phesgo, Tecentriq new indications.
Personalised medicine, diagnostics linkage
Companion-diagnostic integration with Roche Diagnostics Thailand.
UCS high-cost-drug programme access
Specialty oncology inclusion in UCS reimbursement.
Related Market profiles
Peers, parents, partners, agencies, and other Pharmaceuticals actors.
Competitor
Novartis Thailand
Oncology, ophthalmology direct competitor.
Open Market profile β
Competitor
Pfizer Thailand
Oncology, specialty peer.
Open Market profile β
Competitor
GSK Thailand
MNC originator peer.
Open Market profile β
Sector peer
Government Pharmaceutical Organisation (GPO)
Thai state pharmaceutical manufacturer; generics, HIV ARV, biosimilar, Strategic Stockpile; FY2024 revenue ~ $463.8M.
Open Market profile β
Sources + data provenance
Every filing, filing-adjacent register, or trusted industry source cited in this profile.
Roche Thailand β Subsidiary Disclosures
National List of Essential Medicines (NLEM) β Committee, Pricing
Publisher
Ministry of Public Health, Drug Subcommittee
Grade
Primary
As of
2025-12-31
| Source | Publisher | Grade | As of |
|---|---|---|---|
| Roche Thailand β Subsidiary Disclosures | Roche Thailand (MNC subsidiary) | Supporting | 2025-12-31 |
| National List of Essential Medicines (NLEM) β Committee, Pricing | Ministry of Public Health, Drug Subcommittee | Primary | 2025-12-31 |
Reports featuring this profile
Thailand Precision Medicine & Genomics 2027 Market Intelligence
FoundationOne CDx pipeline plus HER2, EGFR test menu; pharma-paired precision-oncology launches with private hospitals and NHSO bundle pilots.
Open report β
Sits alongside 4 other Atlas profilesThailand Pharmaceuticals Market Intelligence
Swiss-parent MNC specialty subsidiary; oncology, biologics, ophthalmology, neuroscience; ~5% Thai market share.
Open report β
Sits alongside 7 other Atlas profilesThailand Pharma Generic vs Branded Deep Dive
Roche Thailand branded innovator MNC.
Open report β
Sits alongside 7 other Atlas profilesRelated Market profiles
competitor
Novartis Thailand
Swiss-parent MNC specialty Thai subsidiary; oncology, cardiovascular, biosimilar; ~6% Thai market value share.
competitor
Pfizer Thailand
US-parent MNC originator Thai subsidiary; oncology, primary care, vaccines; ~7% Thai market value share.
competitor
GSK Thailand
UK-parent MNC originator Thai subsidiary; respiratory, vaccines, HIV, oncology; ~8% Thai market value share.